drugset
Drugs / Ombrabulin
last change Apr 2015 re-read 3 minutes ago

Ombrabulin

also known as AVE8062 · AC7700 · Ombrabulina · Ombrabuline

Other / unclassified

Developed for
cancer · neoplasm · non-small cell lung carcinoma · ovarian carcinoma · sarcoma
Investigated by
Sanofi

Trials 11

today NCT01332656 · Ph 2 NCT01263886 · Ph 2 NCT01293630 · Ph 1 NCT01193595 · Ph 1 NCT01095302 · Ph 1 NCT01021150 · Ph 1 NCT01063946 · Ph 1 NCT00968916 · Ph 1 NCT00719524 · Ph 1 NCT00699517 · Ph 3 NCT01907685 · Ph 1
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 18 trials
Phase 1 NCT01293630 Jan 2011 → Oct 2013 cancer Sanofi Completed No outcome recorded
Phase 1 NCT01193595 Sep 2010 → Oct 2014 cancer Sanofi Completed No outcome recorded
Phase 1 NCT01095302 May 2010 → Dec 2011 cancer Sanofi Completed No outcome recorded
Phase 1 NCT01021150 Mar 2010 → May 2011 cancer Sanofi Completed No outcome recorded
Phase 1 NCT01063946 Jan 2010 → Mar 2011 cancer Sanofi Completed No outcome recorded
Phase 1 NCT00968916 Sep 2009 → Aug 2011 neoplasm Sanofi Completed No outcome recorded
Phase 1 NCT00719524 Jul 2008 → Feb 2013 neoplasm Sanofi Completed No outcome recorded
Phase 1 NCT01907685 Jun 2006 → Feb 2011 neoplasm Sanofi Completed No outcome recorded
Phase 22 trials
Phase 2 NCT01332656 May 2011 → Jul 2014 ovarian carcinoma Sanofi Completed No outcome recorded
Phase 2 NCT01263886 Feb 2011 → Mar 2012 non-small cell lung carcinoma Sanofi Completed No outcome recorded
Phase 31 trial · 1 met primary
Phase 3 NCT00699517 Jun 2008 → Apr 2013 sarcoma Sanofi Completed Met primary

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as OMBRABULIN ClinicalTrials.gov intervention name — accepted as the source's own label NCT00719524 ↗
9

NCT01021150 ↗

NCT01095302 ↗

NCT00699517 ↗

NCT01332656 ↗

NCT01293630 ↗

NCT00968916 ↗

NCT01063946 ↗

NCT01263886 ↗

NCT01193595 ↗
Known as AC7700 ChEMBL registry synonym — accepted as the source's own label CHEMBL572284 ↗
Known as AVE8062 “Ombrabulin (AVE8062) disrupts the vasculature of established tumours” PMID 25864104 ↗ Apr 2015
9

“Drug: Ombrabulin (AVE8062)” NCT01063946 ↗

“Drug: Ombrabulin (AVE8062)” NCT01193595 ↗

“Ombrabulin (AVE8062)” NCT01293630 ↗

“ombrabulin (AVE8062)” NCT01263886 ↗

“ombrabulin (AVE8062)” NCT01021150 ↗

“OMBRABULIN (AVE8062)” NCT01095302 ↗

“OMBRABULIN (AVE8062)” NCT00719524 ↗

“Ombrabulin (AVE8062)” NCT01332656 ↗

NCT01907685 ↗
Known as Ombrabulina ChEMBL registry synonym — accepted as the source's own label CHEMBL572284 ↗
Known as Ombrabuline ChEMBL registry synonym — accepted as the source's own label CHEMBL572284 ↗
Modality Other / unclassified “ombrabulin, a vascular disrupting agent” PMID 24477603 ↗ Jan 2014
Route Intravenous “Route of administration: intravenous infusion” NCT00968916 ↗